Table 1.
Baseline Subject Characteristics
| CKD (n=630) | Control (n=315) | P Value | |
|---|---|---|---|
| Age, y | 69±10 | 70±10 | 0.79 |
| Male, % | 53 | 52 | 0.872 |
| Diabetes, % | 52 | 16 | <0.001 |
| Hypertension, % | 86 | 61 | <0.001 |
| Cigarette smoking, % | 61 | 57 | 0.292 |
| LDL cholesterol, mg/dL | 92 [73 to 115] | 98 [82 to 114] | 0.007 |
| HDL cholesterol, mg/dL | 32 [26 to 40] | 39 [33 to 47] | <0.001 |
| Triglycerides, mg/dL | 134 [96 to 190] | 91 [69 to 129] | <0.001 |
| hsCRP, mg/L | 4 [2 to 9] | 2 [1 to 4] | <0.001 |
| MPO, pmol/L | 134 [89 to 288] | 109 [72.1 to 298.7] | 0.004 |
| Serum arylesterase activity, μmol(L·min) per mL | 94 [77 to 112] | 103 [85 to 121] | <0.001 |
| Serum paraoxonase activity, nmol(L·min) per mL | 474 [275 to 936] | 586 [302 to 1115] | 0.006 |
| Baseline medications, % | |||
| ACE inhibitors/ARBs | 63 | 37 | <0.001 |
| Beta‐blockers | 66 | 42 | <0.001 |
| Statin | 58 | 32 | <0.001 |
| Aspirin | 66 | 55 | <0.001 |
Values expressed as mean±SD or median [interquartile range]. CKD indicates chronic kidney disease; LDL, low‐density lipoprotein; HDL, high‐density lipoprotein; hsCRP, high sensitivity C reactive protein; MPO, myeloperoxidase; ACE, angiotensin‐converting enzyme; ARB, angiotensin II receptor blocker.